Commentary Open Access
Volume 2 | Issue 1 | DOI: https://doi.org/10.33696/immunology.2.015

Tenofovir at the Crossroad of the Therapy and Prophylaxis of HIV and HBV Infections

  • 1KU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Herestraat 49, B-3000 Leuven, Belgium
+ Affiliations - Affiliations

Corresponding Author

Erik De Clercq, erik.declercq@kuleuven.be

Received Date: November 18, 2019

Accepted Date: January 15, 2020


For the treatment and/or prevention of HIV (human immunodeficiency virus) and HBV (hepatitis B virus) infections, 15 tenofovircontaining drug preparations have been commercialized: TDF (tenofovir disoproxil fumarate) and TAF (tenofovir alafenamide) for the therapy of HIV and HBV infections; TDF (or TAF) plus emtricitabine for the prophylaxis of HIV infections; TDF (or TAF) plus emtricitabine plus rilpivirine for the therapy of HIV infections; and several other tenofovir-containing drug combinations have been approved for the therapy of HIV infections: TDF (or TAF) plus emtricitabine plus elvitegravir plus cobicistat; TDF plus emtricitabine plus efavirenz; TAF plus emtricitabine plus bictegravir; TAF plus emtricitabine plus darunavir plus cobicistat; and TDF plus lamivudine with or without efavirenz or doravirine.


HIV therapy; HIV prophylaxis; HBV therapy; Tenofovir disoproxil fumarate (TDF); Tenofovir alafenamide (TAF)

Author Information X